Literature DB >> 1813123

Adenosine infusion during early reperfusion failed to limit myocardial infarct size in a collateral deficient species.

M Goto1, T Miura, E K Iliodoromitis, E L O'Leary, R Ishimoto, D M Yellon, O Iimura.   

Abstract

STUDY
OBJECTIVE: Intracoronary or intravenous adenosine during reperfusion in combination with lignocaine may attenuate "reperfusion injury" and limit myocardial infarct size in the canine heart. The aim of this study was to test whether intravenous adenosine also protects myocardium in the rabbit heart, which lacks xanthine oxidase and significant coronary collaterals in contrast to the canine heart.
DESIGN: Five groups of rabbits underwent a 30 min occlusion of the circumflex coronary artery, followed by reperfusion. In adenosine treated groups, either a high dose of adenosine (0.37 mg.kg-1.min-1) with lignocaine treatment (5 mg intravenously 1 min before coronary occlusion and before reperfusion) or a low dose (0.15 mg.kg-1.min-1) of adenosine with or without lignocaine was infused for 60 min starting 5 min before the onset of reperfusion. Group 1 was untreated, while group 2 received a high dose of adenosine with lignocaine. These groups were reperfused for 3 h. Group 3 was untreated, group 4 received a low dose of adenosine, and group 5 a low dose of adenosine and lignocaine. These groups were reperfused for 72 h. EXPERIMENTAL MATERIAL: 60 anaesthetised open chest rabbits were used. Groups 1 and 2 were killed after 3 h coronary reperfusion. Groups 3, 4, and 5 recovered from surgery for 72 h and were then killed for further study.
MEASUREMENTS AND MAIN RESULTS: The high dose of adenosine reduced mean blood pressure to 44% of baseline value and diminished reactive hyperaemia in the area at risk by "coronary steal". The low dose of adenosine did not significantly alter systemic blood pressure or heart rate. Infarct size did not differ between groups 1 and 2, at 39.7(SD 20.1)% of area at risk v 33.2(15.9)% (by tetrazolium staining), nor between groups 3, 4, and 5: 50.3(12.6)% v 52.7(15.6)% v 47.8(9.3)% (by histology).
CONCLUSION: Neither a high dose nor a low dose of adenosine limited myocardial infarct size in the rabbit heart even when adenosine was combined with lignocaine treatment.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1813123     DOI: 10.1093/cvr/25.11.943

Source DB:  PubMed          Journal:  Cardiovasc Res        ISSN: 0008-6363            Impact factor:   10.787


  9 in total

Review 1.  Adenosine receptors and reperfusion injury of the heart.

Authors:  John P Headrick; Robert D Lasley
Journal:  Handb Exp Pharmacol       Date:  2009

2.  Effects of postconditioning with N,N,N'N'-tetrakis-[2-pyridylmethyl]-ethylenediamine in isolated rat hearts.

Authors:  Joon Hong Kim; Joon Kim; Yong-Hyeon Park; Kook Jin Cheun; Young-Ho Jang
Journal:  Korean J Anesthesiol       Date:  2010-03-29

Review 3.  Adenosine and cardioprotection during reperfusion--an overview.

Authors:  Martín Donato; Ricardo J Gelpi
Journal:  Mol Cell Biochem       Date:  2003-09       Impact factor: 3.396

4.  AMP579 is revealed to be a potent A2b-adenosine receptor agonist in human 293 cells and rabbit hearts.

Authors:  Yanping Liu; Xiulan Yang; Xi-Ming Yang; Sheree Walker; Karina Förster; Michael V Cohen; Thomas Krieg; James M Downey
Journal:  Basic Res Cardiol       Date:  2010-01       Impact factor: 17.165

Review 5.  Signalling pathways and mechanisms of protection in pre- and postconditioning: historical perspective and lessons for the future.

Authors:  Michael V Cohen; James M Downey
Journal:  Br J Pharmacol       Date:  2014-11-24       Impact factor: 8.739

6.  Adenosine Receptor-Mediated Cardioprotection-Current Limitations and Future Directions.

Authors:  Robert D Lasley
Journal:  Front Pharmacol       Date:  2018-04-04       Impact factor: 5.810

7.  Ischaemic preconditioning and postconditioning do not affect adenosine A(1) and A (2A) receptor sensitivity.

Authors:  Niels P Riksen; Abigail Wynne; Derek M Yellon; Derek J Hausenloy
Journal:  Cardiovasc Drugs Ther       Date:  2009-10       Impact factor: 3.727

8.  Targeting reperfusion injury in patients with ST-segment elevation myocardial infarction: trials and tribulations.

Authors:  Derek J Hausenloy; Hans Erik Botker; Thomas Engstrom; David Erlinge; Gerd Heusch; Borja Ibanez; Robert A Kloner; Michel Ovize; Derek M Yellon; David Garcia-Dorado
Journal:  Eur Heart J       Date:  2017-04-01       Impact factor: 29.983

9.  Plasma levels of the cardiovascular protective endogenous nucleoside adenosine are reduced in patients with primary aldosteronism without affecting ischaemia-reperfusion injury: A prospective case-control study.

Authors:  T N A Daniëlle van den Berg; Dick H J Thijssen; Anke C C M van Mil; Petra H van den Broek; Gerard A Rongen; Houshang Monajemi; Jaap Deinum; Niels P Riksen
Journal:  Eur J Clin Invest       Date:  2019-11-25       Impact factor: 4.686

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.